1. Men 65 years of age or older who were diagnosed with prostate cancer in the past 3 month prior to inclusion
2. Gleason's score of 6 or less.
3. Clinical T1C per digital rectal exam.
4. Pre biopsy PSA serum level of 6.0ng/ml or less.
5. The presence of cancer in a single biopsy core of at least 8 taken.
6. The presence of cancer in no more than 10% of the length of the core involved.
7. Patient's consent to engage in active surveillance after being informed of the benefits and potential risks of this approach as well as of alternative lines of therapy.
8. Israeli residence with the readiness to be available for the followup schedule.
You may not be if
Patients who do not meet the above eligibility criteria
